20-F/A: Adlai Nortye Ltd. Files Amendment No. 1 to Form 20-F to Include Audited 2021 Financial Statements

Adlai Nortye Ltd. has filed an amendment to its annual report on Form 20-F to include the audited financial statements for the year ended December 31, 2021, and the corresponding auditor's report.

Summary

• Adlai Nortye Ltd. has amended its annual report on Form 20-F for the year ended December 31, 2023, to include the audited consolidated statements of operations, changes in shareholders' equity, and cash flows for the year ended December 31, 2021, along with the related notes and the auditor's report.
• The amendment does not reflect events occurring after the original filing date and does not modify or update the disclosure therein in any way except for the inclusion of the 2021 financial statements.
• The company had 110,700,805 ordinary shares outstanding as of December 31, 2023, consisting of 93,710,805 Class A ordinary shares and 16,990,000 Class B ordinary shares.
• The company's independent registered accounting firm, Mazars USA LLP, audited the financial statements.
• The company is subject to legal proceedings, investigations, and claims arising from the ordinary course of business from time to time, and may also initiate legal proceedings in order to protect its intellectual property and other rights.
• The company's board of directors has discretion as to whether and when to distribute dividends, subject to certain requirements of Cayman Islands law.
• The company relies upon payments from its operating entities for its cash requirements, including any payment of dividends to its shareholders, and PRC regulations may restrict the ability of its PRC subsidiaries to pay dividends to it.
• The company incurred a loss for the year of $104,871 thousand in 2023, compared to $58,790 thousand in 2022 and $56,678 thousand in 2021.
• Basic and diluted loss per share attributable to ordinary equity holders of the parent was $2.42 in 2023, $2.31 in 2022 and $2.23 in 2021.
• As of December 31, 2023, the company had cash and cash equivalents of $91,492 thousand and total assets of $130,189 thousand.
• The company has accumulated tax losses in Mainland China of $102,647 thousand as of December 31, 2023, that will expire in five to ten years after the loss incurring year.
• The company also has accumulated tax losses in the U.S. of $54,168 thousand as of December 31, 2023, that can be carried forward indefinitely to offset against future taxable profits.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has a reasonable cash position, the increasing losses and accumulated deficit are concerning. The reliance on debt financing and the potential restrictions on dividend payments from PRC subsidiaries further dampen the sentiment.

Positives

• The company maintains cash and cash equivalents at high-quality and accredited financial institutions.
• The company seeks to maintain strict control over its outstanding receivables to minimize credit risk.
• The company's credit facilities were $30,357 thousand as of December 31, 2023.

Negatives

• The company incurred a significant loss of $104,871 thousand in 2023.
• The company's accumulated deficit increased to $373,092 thousand as of December 31, 2023.
• The company relies on payments from operating entities, and PRC regulations may restrict dividend payments.
• The company has a significant amount of financial liabilities measured at fair value through profit or loss.

Risks

• The company may be subject to legal proceedings, investigations, and claims arising from the ordinary course of its business.
• PRC regulations may restrict the ability of the company's PRC subsidiaries to pay dividends.
• Uncertainty about estimates could result in outcomes that could require a material adjustment to the carrying amounts of the assets or liabilities affected in the future.
• The company's ability to utilize deferred tax assets depends on future taxable profits.

Future Outlook

The company's management believes that its available cash and cash equivalents and short-term investments will be sufficient to support its continuous operations and to meet its payment obligations when liabilities fall due within the next twelve months from the date of issuance of these consolidated financial statements.

Industry Context

The document provides financial results for a pharmaceutical company, which is operating in a highly regulated and competitive industry with significant R&D expenses and long development cycles.

Comparison to Industry Standards

• It is difficult to compare Adlai Nortye's results directly to industry standards without knowing specific details about its pipeline, stage of development, and therapeutic areas of focus.
• However, the company's significant R&D expenses are typical for biotech companies in the drug development phase.
• Companies like BeiGene and Zai Lab, which also operate in China and focus on innovative oncology therapies, could be considered peers, but a detailed comparison would require a deeper analysis of their financial statements and business strategies.

Legal Proceedings

• The company may be subject to legal proceedings, investigations, and claims arising from the ordinary course of its business from time to time, and may also initiate legal proceedings in order to protect its intellectual property and other rights.
• Currently, the company is not a party to any actual or threatened legal or administrative proceedings which would have a material and adverse impact on its business, financial condition, or results of operations.

Related Party Transactions

• The RMB40,000 and RMB90,000 non-revolving facility agreements provided by five third party banks were guaranteed by the ultimate significant shareholder, Mr. Yang Lu for the years ended December 31, 2022 and 2023, respectively.

Stakeholder Impact

• Shareholders: The increasing losses and accumulated deficit may negatively impact shareholder value.
• Employees: The company's ability to continue operations and invest in R&D is crucial for job security and growth opportunities.
• Creditors: The company's reliance on debt financing increases the risk for creditors.
• Customers: The company's ability to develop and commercialize new products is essential for meeting customer needs.

Key Dates

Keywords

financial statements, annual report, Adlai Nortye, loss per share, share capital, financial liabilities, tax losses, cash flow, IFRS, audited